| Compound | P21 |
|---|---|
| Category | CNTF-derived peptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers P21, a cntf-derived peptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A peptide fragment derived from ciliary neurotrophic factor investigated in animal models for neurogenesis and cognitive effects.
Mechanism of Action
Proposed to mimic selected CNTF signaling involved in neuronal precursor proliferation.
Research and Evidence
Preclinical animal studies only; no human data.
Safety and Side Effects
No human safety data.
Frequently Asked Questions
What is the evidence tier of P21?
P21 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is P21 an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for P21?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for P21 peptide studies (none registered). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.